Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb signs agreement to sell global diabetes business

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Study finds that triple therapy corrects two core defects in type 2 diabetes

Study finds that triple therapy corrects two core defects in type 2 diabetes

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Pancreatitis and diabetes drugs: an interview with Dr Sonal Singh, Johns Hopkins University School of Medicine

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

New study associates commonly used diabetes drugs with pancreatic cancer risk

New study associates commonly used diabetes drugs with pancreatic cancer risk

GLP-1 pancreatitis concerns justified

GLP-1 pancreatitis concerns justified

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

Oramed to submit new oral insulin IND with FDA

Oramed to submit new oral insulin IND with FDA

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes

EU approves Forxiga for treatment of type 2 diabetes